Citations 11
Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis
Ordaya, Eloy E. , Beam, Elena , Yao, Joseph D. , Vergidis, Paschalis , Vergidis, Paschalis , Beam, Elena , Razonable, Raymund R.
Open Forum Infectious Diseases | June 7, 2022 | Volume: 9 | Issue: 7 | Pages: No page available
Abstract Tixagevimab-cilgavimab is authorized for preexposure prophylaxis against coronavirus disease 2019 (COVID-19) in immunocompromised hosts. Herein, we report the clinical characteristics of 8 patients who developed COVID-19 soon after receiving tixagevimab-cilgavimab. This study emphasizes the need to maintain additional measures to prevent COVID-19 during periods of high severe acute respiratory syndrome coronavirus 2 transmission.